AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03199157
Drug: Fentanyl transdermal patch
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
Trial: NCT02315703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline, 0.5 mL injection administered intramuscularly.
Trial: NCT00805298
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two tablets before surgery, one tablet twice daily on the day after surgery
Trial: NCT00805298
Drug: xyloplyin adrenalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
Trial: NCT00805298
Drug: marcain adrenalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
Trial: NCT00391690
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In case of bone metastases: Zoledronic acid every 4 weeks for 3 months.
Trial: NCT01851070
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04339764
Drug: iPSC-derived RPE/PLGA transplantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iPSC-derived RPE/PLGA transplantation
Trial: NCT00290056
Drug: Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 gram oral supplementation for 6 months.
Trial: NCT03324477
Drug: hypertonic saline 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma
Trial: NCT01055223
Drug: TZD only (RSG or PIO or troglitazone)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug exposure will be inferred from prescription claims. Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
Trial: NCT01055223
Drug: TZD + spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and spirinolactone must overlap by at least 30 days.
Trial: NCT01055223
Drug: TZD + amiloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and Amiloride must overlap by at least 30 days.
Trial: NCT00115752
Drug: Valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00115752
Drug: COX Inhibitor
RxNorm normalized name: COX inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02772107
Drug: first-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）
Trial: NCT01131858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02903355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
Trial: NCT00935948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
Trial: NCT01346540
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGF inhibitor
Trial: NCT01346540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF 1120 placebo
Trial: NCT05898451
Drug: Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: has a direct antitumor effect in vitro and in vivo on various tumor cell lines
Trial: NCT05898451
Drug: Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.
Trial: NCT02437383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
Trial: NCT03505723
Drug: Placebo (Saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
Trial: NCT01056029
Drug: G-202
RxNorm normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
Trial: NCT01130025
Drug: Innohep®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for sub-cutaneous injection, pre-filled syringes. Once daily for 6 months (180 days). 175 anti Xa IU/kg.
Trial: NCT01102270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo capsule prior to sleep
Trial: NCT03133130
Drug: BMT101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMT101 is administered to 6 subjects in each of 4 groups.
Trial: NCT03133130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered to 2 subjects in each of 4 groups.
Trial: NCT02182739
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets or injectable solution
Trial: NCT02707107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03855865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (prefilled syringe, weekly IV administration or oral daily).
Trial: NCT02359604
Drug: PPI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.~The medication used (esomeprazole) in this trial is approved by the FDA
Trial: NCT03469934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered on Day 1 over 1 hour by IV infusion
Trial: NCT03185871
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.
Trial: NCT02284516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match active treatment, BID for 84 days
Trial: NCT01624337
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00406354
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
Trial: NCT03929510
Drug: 14C-PF-06651600 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
Trial: NCT02633813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application for two weeks
Trial: NCT02633813
Drug: Naftin® 2% (Naftifine hydrochloride 2%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application for two weeks
Trial: NCT00660673
Drug: Levodopa-Carbidopa Intestinal Gel (LCIG)
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
Trial: NCT02217722
Drug: Antibiotic cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
Trial: NCT02957279
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the sepsis group, antibiotics were used when needed.
Trial: NCT00713817
Drug: Sativex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Trial: NCT00713817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
Trial: NCT01161641
Drug: ODSH at 0.125 mg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.
Trial: NCT01161641
Drug: ODSH at 0.375 mg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.
Trial: NCT01161641
Drug: ODSH at 0.250 mg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
Trial: NCT01305083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00669656
Drug: Prostate Health Cocktail
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules daily PO up 12 months
Trial: NCT02293161
Drug: GSK2618960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo
Trial: NCT02293161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is Sodium Chloride Intravenous Infusion
Trial: NCT00885287
Drug: Artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
Trial: NCT03602430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.
Trial: NCT01742000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Karinat 500 mg tablet
Trial: NCT03776032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to darbopoetin alfa administered by subcutaneous injection once a week.
Trial: NCT00241358
Drug: AMD3100
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02460705
Drug: Biologically active human fecal material, OpenBiome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplant
Trial: NCT04667910
Drug: 601 1.25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection (intravitreal use)
Trial: NCT04667910
Drug: Ranibizuman 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection (intravitreal use)
Trial: NCT02318537
Drug: Placebo Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching oral solution containing no cannabidiol.
Trial: NCT03012009
Drug: lidocaine hydrochloride 2% with epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00621751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01269411
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00286481
Drug: Lapaquistat acetate and simvastatin
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
Trial: NCT00286481
Drug: Lapaquistat acetate and simvastatin
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
Trial: NCT00286481
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
Trial: NCT00188565
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03170518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet will be administered orally once-daily.
Trial: NCT03918148
Drug: SGLT-2i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin
Trial: NCT03918148
Drug: DPP-4i
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin
Trial: NCT04128085
Drug: TQB3804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A kind of tyrosine kinase inhibitor.
Trial: NCT00134030
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04258241
Drug: Solution with local anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline will be used to perform local infiltration analgesia.
Trial: NCT00134030
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02187744
Drug: Taxotere®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
Trial: NCT04258241
Drug: Solution without local anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution of 0.3 mg of epinephrine and 120 ml of normal saline will be used to perform local infiltration analgesia.
Trial: NCT02187744
Drug: Paraplatin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
Trial: NCT01972568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
Trial: NCT01167309
Drug: LEO 27847
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First in patient
Trial: NCT02289768
Drug: 5-fluorouracil/salicylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02289768
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03977584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
Trial: NCT00306189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC every 6 months
Trial: NCT02215174
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20mg po x1
Trial: NCT04149990
Drug: Entresto Pill
RxNorm normalized name: Entresto Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO other interventions
Trial: NCT06081712
Drug: TNP-2198 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
Trial: NCT02741856
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For more information please see the arm descriptions section.
Trial: NCT04032782
Drug: HM15136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/mL as protein in prefilled syringes
Trial: NCT04032782
Drug: Placebo of HM15136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in prefilled syringes
Trial: NCT00670501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
Trial: NCT00670501
Drug: Calcium Supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
Trial: NCT02865538
Drug: BAY3427080
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02865538
Drug: Placebo (for BAY3427080)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04678856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Trial: NCT02416570
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02416570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00929877
Drug: KETOPROFEN(RP19583)
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
Trial: NCT00929877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
Trial: NCT01518881
Drug: TKM-100201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT01518881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT01904786
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01904786
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00046709
Drug: Smoked Marijuana
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04883736
Drug: Tretinoin Gel Microsphere, 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Trial: NCT04883736
Drug: RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.